Luminex Corporation (LMNX), a developer of biological testing technologies, has released the initial itinerary for a multinational tour designed to exhibit the capabilities of its new MAGPIX analytical instrument. The tour, dubbed “MAGPIX road show,” will allow researchers globally to have a first-hand experience of the novel instrument.
The road show events, which will be hosted across the U.S. and Europe, will feature a presentation from a MAGPIX user and an overview of the instrument along with an explanatory animation of the technology. The MAGPIX road show in Europe has been scheduled in the Netherlands, Germany and Austria. The U.S. events are organized in Boston, Cambridge, San Francisco, San Diego and Philadelphia.
The MAGPIX system (launched in July 2010) leverages Luminex’s proprietary open-architecture xMAP technology and is capable of producing up to 50 tests on a single sample. The versatile multiplexing platform can be used to test both nucleic acids and proteins. MAGPIX has been designed to offer fast, accurate and easily reproducible test results while enabling laboratories to save time and cost.
A recent study demonstrated that the MAGPIX system is more efficient and cost-effective than the traditional Enzyme-linked Immunosorbent Assay (ELISA) method, a biochemical technique used for the detection and analysis of proteins released by cells. The encouraging test results are expected to boost the adoption of MAGPIX by research laboratories.
Texas-based Luminex develops, manufactures and markets proprietary biological testing technologies, which have applications across the life sciences industry. Its xMAP technology enables fast, cost-effective and accurate conduct and analysis of biological tests (bioassays).
Luminex has an extensive product portfolio and a healthy pipeline, which are expected to support growth moving forward. The company continues to expand its xMAP technology-based installed instrument base. Luminex is also spending heavily on assay developments; with some exciting assay products (including NeoPlex 4 and RVP FAST) currently awaiting FDA clearance. We are currently Neutral on the stock.
LUMINEX CORP (LMNX): Free Stock Analysis Report
Zacks Investment Research
